Clinical Trial Search

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Complete Response Rate at 3 Months — 39 percentage of participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Overall Pathological Response Rate — 57.7 % of participants

Primary: Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy — 46 percentage of participants

Primary: Treatment Completion Rate — 67; 53 percentage of participants

Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772

Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Median Overall Survival — 13.9 months

Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants

Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)

Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants

Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants

Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants

Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants

Primary: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0 — 0; 0.07 proportion of participants

Primary: Percentage of Participants With 2-year Progression Free Survival (PFS) — 71.6; 72.3 percentage of participants

Primary: Percentage of Patients Without Distant Metastases by Three Years — 77.8; 84.0 percentage of participants

Primary: Feasibility — 8; 15 participants

Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants

Primary: Complete Response Rate at the End of Induction — 46 percentage of participants

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)

Primary: Progression Free Survival — 8.2 months

Primary: Percent of Participants Who Agree Using the Acceptability Scale — 71.4; 62.5; 62.5; 62.5 percentage of participants

Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…

Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants